Harvard Infectious Diseases in Adults 2021

Description

Harvard Infectious Diseases in Adults 2021

By Harvard Medical School 2021

YOU WILL GET THE COURSE VIA LIFETIME DOWNLOAD LINK (FAST SPEED) AFTER PAYMENT

Infectious Diseases in Adults will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.

OVERVIEW

This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven:

Optimal decision-making in the prevention, diagnosis, and treatment of infectious diseases
Newer antimicrobials and treatment strategies for highly resistant infections
COVID-19: the latest updates
Prevention and treatment of infection in immunocompromised hosts
State-of-the-art approaches to common infections
Clinical approaches to complex, rare, “don’t-miss” infections
New, evolving, and emerging infectious diseases
Update on antifungal diagnostics and therapy
Optimal management of Staph aureus infections
Infections in persons with substance use disorder
What’s new in HIV prevention and management
Musculoskeletal infectious diseases

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.

Highlights of the 2021 Program

Expanded Case-Based and Problem-Solving Education

The 2021 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions of our national experts in Q and A sessions following the lectures and the workshops.

Treating Highly Resistant Infections, including:

MRSA and VISA (vancomycin-intermediate Staph aureus)
Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
Vancomycin-resistant enterococci (VRE)
Aspergillus and non-aspergillus mold infections
Candida auris
Nontuberculous mycobacteria (NTM)

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

Infections in the expanding populations of immunocompromised hosts
Infections in persons with substance use disorders
Infections of travelers and foreign-born persons
Systemic fungal infections
Native and device-related orthopedic infections
Central nervous system (CNS) infections
Ear, nose and throat (ENT) and eye infections
Bronchiectasis and pneumonia
HIV and its infectious and noninfectious complications
PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
Sexually transmitted infections
Hepatitis B and C infections
Tick- and mosquito-borne infections
Vaccines and vaccine-preventable infections
Clostridioides difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

COVID-19
EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
Re-emergence of vaccine-preventable diseases
Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
Global infectious diseases of clinical importance

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

Selecting the best antimicrobial and duration of treatment
Rapid detection and empiric treatment of the life-threatening infectious diseases
Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral?
Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop

Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including: